Life Sciences/Biotech

Group Voices Concern On Michigan House GOP Medicaid Reforms

LANSING - A group of health care providers, insurers, advocates and trade associations submitted a letter this week warning against a proposed 48-month limit on Michigan Medicaid benefits. The Medical Care Advisory Council, in a letter dated Tuesday, expressed concern about the legislation pending in the House Michigan Competitiveness Committee (HB 4714 ) that would

By |2013-05-29T00:00:00-04:00May 29th, 2013|Archive, Life Sciences/Biotech|

Focus On Disease Prevention Creates Market For Disposable Medical Devices

BELMONT - As the health care industry focuses in on disease prevention, care providers are turning to disposable medical devices to help reduce the spread of infections. That shift is providing a key opportunity for a West Michigan manufacturer that?s been serving the medical device industry and others for decades. SSI Electronics Inc. has been

By |2013-05-10T00:00:00-04:00May 10th, 2013|Archive, Life Sciences/Biotech|

Esperion Therapeutics Lands $33 Million In Preferred Stock Financing

ANN ARBOR - Esperion Therapeutics, which is developing new therapies to treat high cholesterol that can be taken as a pill, announced it has completed a $33 million preferred stock financing led by new investor Longitude Capital. Existing investors Aisling Capital, Alta Partners, Domain Associates, Arboretum Ventures and Asset Management also participated in the financing.

By |2013-04-26T00:00:00-04:00April 26th, 2013|Archive, Life Sciences/Biotech|

Great Lakes Health Information Exchange Partners With ModuleMD

LANSING - ModuleMD has partnered with Great Lake Health Information Exchange to create a strategic alliance to electronically connect physician practices with health care systems. Health Information Exchange provides the capability of sharing clinical information electronically among disparate electronic health record systems. ModuleMD provides a flexible electronic health record to independent physician practices nationally. Based

By |2013-04-18T00:00:00-04:00April 18th, 2013|Archive, Life Sciences/Biotech|

FDA Approves Phase II Clinical Trials For Stem Cell Injections To Combat ALS

ANN ARBOR ? The U.S. Food and Drug Administration has approved the Phase II clinical trail of the nation's first clinical trial of stem cell injections in patients with the deadly degenerative disease known as amyotrophic lateral sclerosis, often called ALS or Lou Gehrig's disease. Approval paves the way for UM to become the second

By |2013-04-18T00:00:00-04:00April 18th, 2013|Archive, Life Sciences/Biotech|

Blaze Medical Devices Adds Two To Advisory Board

ANN ARBOR - Blaze Medical Devices has added two new members to its advisory board, CPA Paul Glantz and finance professional Terry Cross. Blaze is a medical device company focusing on increasing the efficacy and safety of transfusions while reducing transfusion-related costs and reducing the use of blood. Blood units differ in properties based on

By |2013-04-12T00:00:00-04:00April 12th, 2013|Archive, Life Sciences/Biotech|

Health-Technology Forum April 10 In Midland

MIDLAND - The MidMichigan Innovation Center and BlueWater Angels along with the Office for Innovation at Covenant HealthCare will be co-hosting a health technology forum April 10 to showcase five new Michigan companies - each company having potential to dramatically impact the future of medicine. One of the roles of the Covenant HealthCare Office for

By |2013-04-05T00:00:00-04:00April 5th, 2013|Archive, Life Sciences/Biotech|

Investing In Healthcare: Opportunities From A Venture Capital Perspective

ANN ARBOR ? The next BioArbor on April 10 will feature two seasoned venture capital investors, both with capital to invest and novel investment strategies. Both are based outside of Michigan, yet have made local investments and are actively seeking opportunities to invest in Michigan. The event will offer a great platform to hear about

By |2013-04-03T00:00:00-04:00April 3rd, 2013|Archive, Life Sciences/Biotech|

Michigan Biotechnology Institute, MSU Ink Deal To Develop Bio-Based Tech

LANSING - The Michigan Biotechnology Institute and Michigan State University have entered into a new collaborative arrangement, under which promising bio-based technologies will be accelerated from the laboratory to commercial deployment. The agreement combines MSU?s research expertise with MBI?s ?derisking? process and advanced bioprocessing to quickly and efficiently demonstrate the market-readiness of new technologies. Intellectual

By |2013-03-22T00:00:00-04:00March 22nd, 2013|Archive, Life Sciences/Biotech|